Viewing Study NCT06158061


Ignite Creation Date: 2025-12-24 @ 12:08 PM
Ignite Modification Date: 2025-12-27 @ 9:24 PM
Study NCT ID: NCT06158061
Status: UNKNOWN
Last Update Posted: 2023-12-06
First Post: 2023-11-28
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Assessment of Serum and Tissue Tryptase Levels in Acne Vulgaris Patients
Sponsor: Sohag University
Organization:

Study Overview

Official Title: Assessment of Serum and Tissue Tryptase Levels in Acne Vulgaris Patients
Status: UNKNOWN
Status Verified Date: 2023-11
Last Known Status: NOT_YET_RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Acne vulgaris is an inflammatory disorder of pilosebaceous glands. Acne is a highly prevalent inflammatory disease affecting approximately 9.4% of the world's population , and estimated up to 90% among adolescents. By natural course acne starts at 7-12 ages and mostly resolves by the third decade of individuals life .

Mast cells may play important role in maintenance of physiological functions of our body; they also have a role in pathological and inflammatory mechanisms of many diseases. Tryptase is suggested to be important for survival as no tryptase-deficient human subject has yet been reported. Tryptase is mainly synthesized by mast cells but a very low amount may originate in basophil with no interference with total levels of the enzyme. Tryptase is currently considered as a metabolic signaling and effector mediator for acute mast cell degranulation and late phase of allergy and inflammation .
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: